JP2022502066A5 - - Google Patents

Info

Publication number
JP2022502066A5
JP2022502066A5 JP2021519114A JP2021519114A JP2022502066A5 JP 2022502066 A5 JP2022502066 A5 JP 2022502066A5 JP 2021519114 A JP2021519114 A JP 2021519114A JP 2021519114 A JP2021519114 A JP 2021519114A JP 2022502066 A5 JP2022502066 A5 JP 2022502066A5
Authority
JP
Japan
Prior art keywords
vaccinia virus
virus vector
vector according
scr4
scr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519114A
Other languages
English (en)
Japanese (ja)
Other versions
JP7410139B2 (ja
JP2022502066A (ja
Filing date
Publication date
Priority claimed from GBGB1816547.2A external-priority patent/GB201816547D0/en
Application filed filed Critical
Publication of JP2022502066A publication Critical patent/JP2022502066A/ja
Publication of JP2022502066A5 publication Critical patent/JP2022502066A5/ja
Application granted granted Critical
Publication of JP7410139B2 publication Critical patent/JP7410139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519114A 2018-10-10 2019-10-10 癌治療のための修飾b5r遺伝子を有する腫瘍溶解性ワクシニアウイルス Active JP7410139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816547.2 2018-10-10
GBGB1816547.2A GB201816547D0 (en) 2018-10-10 2018-10-10 Oncolytic virus for the treatment of cancer
PCT/GB2019/052877 WO2020074902A1 (en) 2018-10-10 2019-10-10 Oncolytic vaccinia virus with modified b5r gene for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2022502066A JP2022502066A (ja) 2022-01-11
JP2022502066A5 true JP2022502066A5 (cg-RX-API-DMAC7.html) 2022-10-04
JP7410139B2 JP7410139B2 (ja) 2024-01-09

Family

ID=64397608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519114A Active JP7410139B2 (ja) 2018-10-10 2019-10-10 癌治療のための修飾b5r遺伝子を有する腫瘍溶解性ワクシニアウイルス

Country Status (8)

Country Link
US (1) US12509704B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863669A1 (cg-RX-API-DMAC7.html)
JP (1) JP7410139B2 (cg-RX-API-DMAC7.html)
KR (1) KR102937548B1 (cg-RX-API-DMAC7.html)
CN (1) CN113453713A (cg-RX-API-DMAC7.html)
CA (1) CA3123973A1 (cg-RX-API-DMAC7.html)
GB (1) GB201816547D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020074902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023313118A1 (en) * 2022-07-27 2025-03-06 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5547862A (en) 1993-07-29 1996-08-20 Ambion Inc. Vectors containing multiple promoters in the same orientation
FR2757178B1 (fr) 1996-12-13 1999-03-05 Centre Nat Rech Scient Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament
US5955310A (en) 1998-02-26 1999-09-21 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide in a bacillus cell
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100354441B1 (en) 2000-12-27 2002-09-28 Samsung Electronics Co Ltd Method for fabricating spin-on-glass insulation layer of semiconductor device
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
ATE508190T1 (de) 2004-03-05 2011-05-15 Benitec Inc Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
EP1933857A2 (en) 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20090196905A1 (en) 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
CN101658670A (zh) 2008-08-25 2010-03-03 中国疾病预防控制中心性病艾滋病预防控制中心 基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗
US8623381B2 (en) * 2008-09-19 2014-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Viral strains derived from the vaccinia virus Lister VACV-107 and uses thereof
EP2199400A1 (en) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
US20100291182A1 (en) 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションDose Medical Corporation 薬剤溶出眼内インプラント
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
ES2362525B8 (es) 2009-10-08 2013-01-03 Azurebio, S.L. Formulación de medicamentos en forma de agujas percutaneas penetrantes.
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
JP5652830B2 (ja) 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロrna制御組換えワクシニアウイルス及びその使用
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
WO2012083081A1 (en) 2010-12-16 2012-06-21 Novozymes, Inc. Promoters for expressing genes in a fungal cell
CN103110939A (zh) 2012-10-23 2013-05-22 郑州大学 诱导肿瘤特异性免疫的疫苗及其应用
WO2014165308A2 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
US10370647B2 (en) * 2015-07-22 2019-08-06 National University Corporation Tottori University Host regulatory factor that enhances replication and/or propagation of vaccinia virus
AU2017272721B2 (en) * 2016-05-30 2023-03-30 Astellas Pharma Inc. Novel genetically engineered vaccinia viruses
TW201825511A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒

Similar Documents

Publication Publication Date Title
Attermann et al. Human endogenous retroviruses and their implication for immunotherapeutics of cancer
KR101114784B1 (ko) 아데노바이러스 벡터 백신
Bermúdez-Humarán et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production
JP2006141398A5 (cg-RX-API-DMAC7.html)
JP2022501074A5 (cg-RX-API-DMAC7.html)
JP2017525336A5 (cg-RX-API-DMAC7.html)
JP2025023916A5 (cg-RX-API-DMAC7.html)
JP2021535749A5 (cg-RX-API-DMAC7.html)
JP2007511216A5 (cg-RX-API-DMAC7.html)
US20100047289A1 (en) Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
Lin et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity
Lui et al. Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor
JP2022513321A5 (cg-RX-API-DMAC7.html)
Namkoong et al. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11
JP2017522326A5 (cg-RX-API-DMAC7.html)
JP4719876B2 (ja) Hlaクラスii拘束性wt1抗原ペプチド
Ma et al. Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells
KR100788930B1 (ko) 항암 조성물
JP2024534189A5 (cg-RX-API-DMAC7.html)
WO2021092719A1 (zh) 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白
CZ20011521A3 (cs) Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek
Xue et al. Anti-tumour research of recombinant BCG using BZLF1 and hGM-CSF fusion genes
Montero et al. Immune effects observed after the injection of plasmids coding for rainbow trout (Oncorhynchus mykiss) CK5B, CK6 and CK7A chemokines demonstrate their immunomodulatory capacity and reveal CK6 as a major interferon inducer
TWI259206B (en) A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof
Paul et al. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer